Keyphrases
Previously Treated
100%
Advanced Gastric Cancer
100%
Everolimus
100%
Randomized Double-blind
100%
Placebo
33%
Best Supportive Care
33%
Asia
22%
Two-line
22%
Phase II Study
22%
Safety Profile
22%
Overall Survival
22%
Hazard Ratio
22%
Systemic Chemotherapy
22%
Rest of the World
22%
Adverse Events
11%
Median Overall Survival
11%
Overall Response Rate
11%
Median Progression-free Survival
11%
Anemia
11%
Progression-free Survival
11%
Disease Progression
11%
Previous Chemotherapy
11%
MTOR Inhibitor
11%
Decreased Appetite
11%
Pharmacology, Toxicology and Pharmaceutical Science
Everolimus
100%
Abdominal Cancer
100%
Overall Survival
33%
Placebo
33%
Progression Free Survival
22%
Chemotherapy
22%
Malignant Neoplasm
11%
Adverse Event
11%
Anemia
11%
Disease Exacerbation
11%
Patient History of Chemotherapy
11%
Mammalian Target of Rapamycin Inhibitor
11%
Decreased Appetite
11%